Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The new plant will manufacture high-quality Type I borosilicate glass tubing
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Subscribe To Our Newsletter & Stay Updated
